Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-04-02 Purchase |
2025-04-04 10:54 am |
Eterna Therapeutics Inc. | ERNA | Cherington Charles 10% Owner |
3,768,397 | $0.1046 | $394,174 | 20,401,602 (Direct) |
View |
| 2024-10-29 Purchase |
2024-11-05 12:42 pm |
Eterna Therapeutics Inc. | ERNA | Cherington Charles 10% Owner |
13,252,112 | $0 | $0 | 29,823,881 (Direct) |
View |
| 2022-12-02 Purchase |
2022-12-06 9:02 pm |
Eterna Therapeutics Inc. | ERNA | Cherington Charles Director 10% Owner |
261,756 | $3.28 | $858,560 | 1,079,977 (Direct) |
View |
| 2022-12-02 Purchase |
2022-12-06 6:52 pm |
Eterna Therapeutics Inc. | ERNA | Singer Nicholas Jason Director |
283,286 | $3.28 | $929,178 | 832,786 (Indirect) |
View |
| 2022-12-02 Purchase |
2022-12-05 6:05 pm |
Eterna Therapeutics Inc. | ERNA | HALPERN JOHN D 10% Owner |
335,920 | $3.28 | $1,101,818 | 1,123,006 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-02-07 Option Award |
2025-02-10 7:00 pm |
N/A 2035-02-07 |
Eterna Therapeutics Inc. | ERNA | Wexler William A. Director |
124,533 | $0 | 124,533 (Direct) |
View |
| 2025-02-07 Option Award |
2025-02-10 7:00 pm |
N/A 2035-02-07 |
Eterna Therapeutics Inc. | ERNA | Gurrola Sandra M Sr. VP of Finance |
150,000 | $0 | 150,000 (Direct) |
View |
| 2025-02-07 Option Award |
2025-02-10 7:00 pm |
N/A 2035-02-07 |
Eterna Therapeutics Inc. | ERNA | Bristol James Arthur Director |
72,074 | $0 | 72,074 (Direct) |
View |
| 2025-02-07 Option Award |
2025-02-10 7:00 pm |
N/A 2035-02-07 |
Eterna Therapeutics Inc. | ERNA | Cicala Peter Director |
51,485 | $0 | 51,485 (Direct) |
View |
| 2025-02-07 Option Award |
2025-02-10 7:00 pm |
N/A 2035-02-07 |
Eterna Therapeutics Inc. | ERNA | Luther Sanjeev President & CEO |
1,123,350 | $0 | 1,123,350 (Direct) |
View |
| 2025-01-13 Option Award |
2025-01-14 5:01 pm |
N/A 2035-01-13 |
Eterna Therapeutics Inc. | ERNA | Ratner Elena Director |
140,078 | $0 | 140,078 (Direct) |
View |
| 2024-10-29 Conversion |
2024-11-05 12:42 pm |
N/A 2025-09-24 |
Eterna Therapeutics Inc. | ERNA | Cherington Charles 10% Owner |
1,368,626 | $0 | 29,823,881 (Direct) |
View |
| 2024-10-29 Conversion |
2024-11-05 12:42 pm |
N/A N/A |
Eterna Therapeutics Inc. | ERNA | Cherington Charles 10% Owner |
2,819,546 | $0.5 | 29,823,881 (Direct) |
View |
| 2024-06-21 Exercise |
2024-06-25 4:32 pm |
N/A N/A |
Eterna Therapeutics Inc. | ERNA | Gurrola Sandra M Sr. VP of Finance |
437 | $0 | 1,622 (Direct) |
View |
| 2024-06-21 Tax Withholding |
2024-06-25 4:32 pm |
N/A N/A |
Eterna Therapeutics Inc. | ERNA | Gurrola Sandra M Sr. VP of Finance |
180 | $1.94 | 1,622 (Direct) |
View |
| 2024-04-26 Option Award |
2024-04-29 4:31 pm |
N/A 2034-04-26 |
Eterna Therapeutics Inc. | ERNA | Cicala Peter Director |
88,946 | $0 | 88,946 (Direct) |
View |
| 2024-04-26 Option Award |
2024-04-29 4:30 pm |
N/A 2034-04-26 |
Eterna Therapeutics Inc. | ERNA | Gurrola Sandra M Sr. VP of Finance |
80,000 | $0 | 80,000 (Direct) |
View |
| 2024-04-26 Option Award |
2024-04-29 4:30 pm |
N/A 2034-04-26 |
Eterna Therapeutics Inc. | ERNA | Bristol James Arthur Director |
124,525 | $0 | 124,525 (Direct) |
View |
| 2024-01-01 Option Award |
2024-01-03 5:02 pm |
N/A 2034-01-01 |
Eterna Therapeutics Inc. | ERNA | Luther Sanjeev President and CEO |
1,685,218 | $0 | 1,685,218 (Direct) |
View |
| 2024-01-01 Option Award |
2024-01-03 5:01 pm |
N/A 2034-01-01 |
Eterna Therapeutics Inc. | ERNA | Clarke Dorothy J General Counsel Director |
168,521 | $0 | 168,521 (Direct) |
View |
| 2023-12-14 Expired |
2023-12-20 10:05 am |
2023-07-14 2028-07-14 |
Eterna Therapeutics Inc. | ERNA | Cherington Charles 10% Owner |
2,831,204 | $0 | 8,957,180 (Direct) |
View |
| 2023-12-14 Option Award |
2023-12-18 9:38 pm |
2023-06-02 2028-06-02 |
Eterna Therapeutics Inc. | ERNA | Freebird Partners LP Freebird Investments LLC HUFF CURTIS W 10% Owner |
949,402 | $0 | 5,622,833 (Direct) |
View |
| 2023-06-21 Tax Withholding |
2023-06-23 8:30 pm |
N/A N/A |
Eterna Therapeutics Inc. | ERNA | Gurrola Sandra M Vice President of Finance |
179 | $2.48 | 1,802 (Direct) |
View |
| 2023-06-21 Exercise |
2023-06-23 8:30 pm |
N/A N/A |
Eterna Therapeutics Inc. | ERNA | Gurrola Sandra M Vice President of Finance |
438 | $0 | 1,802 (Direct) |
View |
Ownership |
2023-04-04 5:03 pm |
N/A N/A |
Eterna Therapeutics Inc. | ERNA | Freebird Partners LP Freebird Investments LLC HUFF CURTIS W 10% Owner |
0 | $0 | 697,510 (Direct) |
View |
Ownership |
2023-03-06 4:01 pm |
N/A N/A |
Eterna Therapeutics Inc. | ERNA | DENNY GEORGE P III 10% Owner |
0 | $0 | 460,413 (Indirect) |
View |
| 2023-01-12 Option Award |
2023-01-13 7:30 pm |
N/A 2033-01-12 |
Eterna Therapeutics Inc. | ERNA | Angel Matthew President and CEO |
132,003 | $0 | 132,003 (Direct) |
View |
| 2022-09-20 Exercise |
2022-09-21 7:00 pm |
N/A N/A |
Brooklyn ImmunoTherapeutics Inc. | BTX | Sidhu Roger Chief Medical Officer |
20,163 | $0 | 80,650 (Direct) |
View |
| 2022-08-01 Option Award |
2022-08-03 8:01 pm |
N/A 2032-08-01 |
Brooklyn ImmunoTherapeutics Inc. | BTX | Angel Matthew Interim President and CEO |
2,487,003 | $0 | 2,487,003 (Direct) |
View |
| 2022-08-01 Option Award |
2022-08-03 8:01 pm |
N/A 2032-08-01 |
Brooklyn ImmunoTherapeutics Inc. | BTX | Cherington Charles Director |
380,900 | $0 | 380,900 (Direct) |
View |
| 2022-08-01 Option Award |
2022-08-03 8:01 pm |
N/A 2032-08-01 |
Brooklyn ImmunoTherapeutics Inc. | BTX | Fiore Gregory Director |
260,900 | $0 | 260,900 (Direct) |
View |